Patents by Inventor Rosana Kapeller-Libermann

Rosana Kapeller-Libermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7351566
    Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: April 1, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
  • Patent number: 7329529
    Abstract: The invention provides isolated nucleic acids molecules that encode novel ubiquitin protease polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the ubiquitin protease nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a ubiquitin protease sequence of the invention has been introduced or disrupted. The invention still further provides isolated ubiquitin protease proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: February 12, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rosana Kapeller-Libermann
  • Publication number: 20070292845
    Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 6, 2002
    Publication date: December 20, 2007
    Inventor: Rosana Kapeller-Libermann
  • Patent number: 7301016
    Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: November 27, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
  • Patent number: 7288392
    Abstract: The invention relates to novel kinase nucleic acid sequences and proteins. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: October 30, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Rosana Kapeller-Libermann, Mark Williamson
  • Patent number: 7282360
    Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: October 16, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
  • Publication number: 20070212728
    Abstract: The invention provides isolated nucleic acids molecules, designated BRE nucleic acid molecules, which encode novel biotin enzyme-related molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BRE nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a BRE gene has been introduced or disrupted. The invention still further provides isolated BRE proteins, fusion proteins, antigenic peptides and anti-BRE antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 4, 2007
    Publication date: September 13, 2007
    Inventors: Rachel Meyers, Laura Rudolph-Owen, Rosana Kapeller-Libermann
  • Publication number: 20070166748
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection, with obesity disorders are also disclosed.
    Type: Application
    Filed: March 9, 2007
    Publication date: July 19, 2007
    Inventors: Ruth GIMENO, Zhidan WU, Rosana Kapeller-Libermann, Brian Hubbard
  • Patent number: 7241585
    Abstract: The invention relates to a novel kinase nucleic acid sequence and protein. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: July 10, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rosana Kapeller-Libermann
  • Patent number: 7235634
    Abstract: The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: June 26, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Rosana Kapeller-Libermann, David White, Kyle J. MacBeth
  • Publication number: 20070099274
    Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.
    Type: Application
    Filed: December 11, 2006
    Publication date: May 3, 2007
    Inventors: Rachel Meyers, Peter Olandt, Rosana Kapeller-Libermann, Rory Curtis, Mark Williamson, Nadine Weich
  • Patent number: 7198930
    Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: April 3, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rosana Kapeller-Libermann
  • Patent number: 7198929
    Abstract: The invention provides an isolated nucleic acid molecule, designated as a kinase nucleic acid molecule, which encodes a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing kinase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. The invention still further provides isolated 14790 proteins, fusion proteins, antigenic peptides and anti-kinase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: April 3, 2007
    Assignees: Millennium Pharmaceuticals, Bayer Corporation
    Inventors: William James Cook, Rosana Kapeller-Libermann, Helga Rubsamen-Waigmann, Frank Spaltmann
  • Publication number: 20070065848
    Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.
    Type: Application
    Filed: July 26, 2006
    Publication date: March 22, 2007
    Inventors: Rachel Meyers, Kyle MacBeth, Rory Curtis, Laura Rudolph-Owen, Nadine Weich, Peter Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph Carroll
  • Publication number: 20070037203
    Abstract: The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted.
    Type: Application
    Filed: October 19, 2006
    Publication date: February 15, 2007
    Inventors: Rosana Kapeller-Libermann, John Hunter, Rachel Meyers, Laura Rudolph-Owen, Rory Curtis, Peter Olandt, Fong-Ying Tsai, Katherine Galvin, Miyoung Chun, Mark Williamson, Inmaculada Silos-Santiago, Rajasekhar Bandaru
  • Publication number: 20060240464
    Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 5, 2006
    Publication date: October 26, 2006
    Inventors: Rachel Meyers, Joseph Carroll, William Cook, Rosana Kapeller-Libermann, Nadine Weich, Rajasekhar Bandaru
  • Publication number: 20060211050
    Abstract: The invention provides isolated nucleic acid molecules, designated COE-2 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a COE-2 gene has been introduced or disrupted. The invention still further provides isolated COE-2 proteins, fusion proteins, antigenic peptides and anti-COE-2 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 21, 2006
    Inventors: Rosana Kapeller-Libermann, Inmaculada Silos-Santiago
  • Patent number: 7094587
    Abstract: The invention provides isolated nucleic acids molecules, designated 16002 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16002 gene has been introduced or disrupted. The invention still further provides isolated 16002 proteins, fusion proteins, antigenic peptides and anti-16002 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: August 22, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
  • Publication number: 20060183210
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: December 7, 2005
    Publication date: August 17, 2006
    Inventors: Ruth Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian Hubbard
  • Patent number: 7081344
    Abstract: The invention provides isolated nucleic acid molecules, designated COE-2 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a COE-2 gene has been introduced or disrupted. The invention still further provides isolated COE-2 proteins, fusion proteins, antigenic peptides and anti-COE-2 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: July 25, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Inmaculada Silos-Santiago